Vikram Karnani - 10 Feb 2026 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting relationship: President and CEO, Director
Issuer ticker: COLL
Reported as of: 10 Feb 2026
Net transaction value: -$528,088
SEC form: 4
Accepted by SEC: 12 Feb 2026, 16:30:21 UTC
Prior SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Colleen Tupper as Attorney-In-Fact For Vikram Karnani

Key filing fact

Vikram Karnani filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 12 Feb 2026.

Key facts

This page summarizes Vikram Karnani's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 16:30.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: -$528,088.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001699488 Primary reporting owner

Karnani Vikram

Relationship: President and CEO, Director
Address: C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON
Signature: /s/ Colleen Tupper as Attorney-In-Fact For Vikram Karnani
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COLL transaction

Common Stock

Award

Transaction value: $0
Shares: +79,264
Change %: +81%
Price: $0.000000
Shares after: 176,629
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

COLL transaction

Common Stock

Award

Transaction value: $0
Shares: +32,531
Change %: +18%
Price: $0.000000
Shares after: 209,160
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F3

COLL transaction

Common Stock

Tax liability

Transaction value: $528,088
Shares: -11,296
Change %: -5.4%
Price: $46.75
Shares after: 197,864
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Footnote F2

Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan.

Footnote F3

Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.

Footnote F4

Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.